OncNGS
  • Home
  • Call for tenders
  • About OncNGS
  • Phases
    • OMC
  • Matchmaking: find a partner!
  • FAQ
  • News
  • Contact
  • Workspace
  • Home
  • Call for tenders
  • About OncNGS
  • Phases
    • OMC
  • Matchmaking: find a partner!
  • FAQ
  • News
  • Contact
  • Workspace

European Call for the future Next Generation Sequencing (NGS) solutions for cancer

  • Pre-commercial Procedure
  • Phase 0
  • Phase I
  • Phase II
  • Phase III

Pre-commercial Procedure

OncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers.

View more

Phase 0 : Curiosity Driven Research

A new call for tender will be open soon! Learn more.

We are currently in Phase 0, a preparation stage. Before the opening of the Call for tender, we defined the needs by collecting feedback of the buyer’s group during the OMC (Open Market Consultation) and translate them into requirements and specifications to direct analysis and technical dialogue with the industry. The OMC is now closed. A ‘Frequently Asked Questions’ page has been created to gather and respond all the questions we received during the OMC. A matchmaking page is also available for organisations  interested in finding partners to create consortia and jointly participate in the oncNGS PCP tender.

View more

Phase I : Solution design

Concepts elaboration into the competitive solutions.
Minimum 4 designs will be selected.

Overall duration : 12 months – Execution : 6 months

View more

Phase II : Prototype development

Development of the well outlined and functioning prototypes.
Minimum 3 designs will be selected.

Overall duration : 15 months – Execution : 12 months

View more

Phase III : Clinical validation of a limited set of pre-commercial devices

the functional and technical properties of the selected solutions will be evaluated in an operational environment.
Minimum of 2 pre-commercial devices will be deployed.

Overall duratiob : 18 months – Execution : 15 months

View more

About

The oncNGS consortium groups several buyers in 5 EU countries to challenge the market to develop novel affordable solutions to provide the most advanced NGS tests for cancer patients. We wish to co-develop an EU innovative tender for liquid biopsy diagnostics based on complex NGS-driven DNA profiling within a pre-commercial procurement Horizon-2020 financed project.

View more

Latest news

New call for tenders to be launched & suppliers information day 29/06/2022
2022-06-22

New call for tenders to be launched & suppliers information day 29/06/2022

The OncNGS consortium launched a Call for Tender in[…]

by Editorial team
oncNGS – Spring update
2022-03-29

oncNGS – Spring update

OncNGS partners took the advantage of the improvement of[…]

by Editorial team
oncNGS Call for tender: deadline extended & other updates
2022-01-17

oncNGS Call for tender: deadline extended & other updates

Please find below the last updates of the oncNGS[…]

by Editorial team

Get in touch

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874467

Follow us :

© OncNGS

  • Privacy policy
  • Disclaimer